Intercept Pharma (ICPT) Misses Q1 EPS by 52c; Revenues Beat; Raises FY19 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to Intercept Pharma (ICPT) Misses Q1 EPS by 52c; Revenues Beat; Raises FY19 Revenue Guidance

Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

May 8, 2019 7:01 AM EDT

Positive results from pivotal Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to NASH

New Drug Application (NDA) filing in the U.S. for OCA in NASH projected in the third quarter of 2019 

Worldwide Ocaliva net sales of $51.8 million in the first quarter of 2019 representing 47% growth versus the prior year quarter 

Increasing 2019 Ocaliva net sales guidance range to between $235 and $245 million 

Updating 2019 non-GAAP adjusted operating expenses guidance range to between $470 and $500... More